加载中
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
前收盘价
US$82.37
−US$0.06 · -0.07%
盘中时间采用ET。市场数据可能有所延迟。
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
日内区间
当前US$82.37
52周区间
当前US$82.37
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
32
偏贵
情绪
58
多空交织
风险
35
中等风险
动量
70
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
日内区间
当前US$82.37
52周区间
当前US$82.37
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 203.6万 USD | 623.5万 USD | 282.6万 USD | 641.7万 USD | 147.6万 USD |
| 毛利 | 203.6万 USD | 623.5万 USD | 282.6万 USD | 641.7万 USD | 147.6万 USD |
| 研究与开发 | 1.46亿 USD | 8310.5万 USD | 3284.1万 USD | 2937.9万 USD | 1260.6万 USD |
| 销售、一般及管理费用 | 3433.1万 USD | 2499.4万 USD | 1815.9万 USD | 674.3万 USD | 195.6万 USD |
| 营业费用 | 1.8亿 USD | 1.08亿 USD | 5100万 USD | 3612.2万 USD | 1456.2万 USD |
| 利息收入 | 1611.9万 USD | 1736.5万 USD | 476.4万 USD | 114.5万 USD | 10万 USD |
| 折旧和摊销 | 42.8万 USD | 41.2万 USD | 35.5万 USD | 14.7万 USD | 202万 USD |
| 营业利润 | −1.78亿 USD | −1.02亿 USD | −4817.4万 USD | −2970.5万 USD | −1308.6万 USD |
| 净利润 | −1.62亿 USD | −8496.9万 USD | −4355.5万 USD | −2847.6万 USD | −1310.9万 USD |
公司数据更新于 2026年10月11日。
近期已公布业绩
近期已公布业绩
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1.75亿0.01%2.3万亿 USD0.03%US$381.94+0.63%
State Street SPDR S&P Biotech ETFXBI1.15亿1.17%98.74亿 USD0.35%US$153.77+3.00%
iShares Russell 2000 ETFIWM1.03亿0.13%787.4亿 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF4897.67万0.05%954亿 USD0.05%US$235+0.80%
iShares Russell 2000 Growth ETFIWO3603.06万0.26%139.17亿 USD0.24%US$356.78+0.94%
Vanguard Russell 2000 ETFVTWO2872.44万0.16%180亿 USD0.06%US$112.66+0.50%
Schwab U.S. Small-Cap ETFSCHA2450.23万0.11%218.24亿 USD0.03%US$32.79+0.40%
T. Rowe Capital Appreciation Equity ETFTCAF1323.16万0.15%91.1亿 USD0.31%US$43.59+0.90%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAT. Rowe Capital Appreciation Equity ETFTCAFAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
